Case Study

Inoperable Optic Pathway Glioma: A Seven-Year-Old Male with >35 Years Overall Survival Following Treatment with Antineoplastons

Stanislaw R. Burzynski
Burzynski Clinic, USA
* Corresponding author
Gregory S. Burzynski
Burzynski Clinic, USA
Tomasz J. Janicki
Burzynski Clinic, USA
Samuel W. Beenken
Oncology Writings, USA
DOI icon 10.24018/clinicmed.2023.4.5.312

Read Counter
506

Downloads
181

Citations

Share

Article Sidebar

Submitted 2023-08-28
Published 2023-10-17

Read counter = 506 times

Table of Contents

Article Main Content

Optic pathway glioma (OPG) is a low-grade tumor developing along the pre-cortical optic pathways and can involve the optic nerve, optic chiasm, optic tracts, and hypothalamus.

Objective: A male child with newly diagnosed and unresectable OPG is presented to 1) review the earliest use of Antineoplastons A10 and AS2-1 for the treatment of brain tumors and 2) demonstrate the efficacy of Antineoplastons in the treatment of OPG. On April 18, 1988, a seven-year-old male child presented to the Burzynski Clinic (BC) with headaches. Based on prior, non-enhanced MRIs and biopsy, an unresectable suprasellar OPG was diagnosed. Antineoplaston therapy was started on a “proof of principle” basis. Tumor response was measured by magnetic resonance imaging (MRI) scans of the brain.

Results: A brain MRI, performed on May 31, 1989, demonstrated an enhancing suprasellar nodule measuring 4.37 cm2. On August 24, 1990, brain MRI demonstrated a 0.96 cm2 enhancing nodule, indicating the achievement of a partial response (PR). Following higher dose intravenous (IV) and oral Antineoplastons, brain MRI performed on January 24, 1997, demonstrated a residual 0.4 cm2 enhancing nodule, indicating an enduring PR. All Antineoplaston therapy was discontinued on August 21, 2000. At last follow-up, > 35 years since the start of Antineoplaston therapy, the patient was healthy and showed no evidence of tumor progression. “Proof of principle” Antineoplaston therapy utilized in a seven-year-old male with unresectable OPG produced an objective response (OR) and prolonged overall survival. Antineoplaston therapy is an attractive therapeutic option for children with OPG.

Keywords: Antineoplastons Inoperable optic pathway glioma Low-grade glioma Phase II studies

References

  1. Robert-Boire V, Rosca L, Samson Y, Ospina LH, Perreault S. Clinical presentation and outcome of patients with optic pathway glioma. Pediatr Neurol. 2017;75:55–60.
     Google Scholar
  2. doi: 10.1016/j.pediatrneurol.2017.06.019.
     Google Scholar
  3. Binning MJ, Liu JK, Kestle JR, Brockmeyer DL, Walker ML. Optic pathway gliomas: A review. Neurosurg Focus. 2007;23:E2. doi: 10.3171/FOC-07/11/E2.
     Google Scholar
  4. Fried I, Tabori U, Tihan T, Reginald A, Bouffet E. Optic pathway gliomas: A review. CNS Oncol. 2013;2:143–159. doi: 10.2217/cns.12.47.
     Google Scholar
  5. Campen CJ, Gutmann DH. Optic pathway gliomas in neurofibromatosis type 1. J Child Neurol. 2018;33:73–81. doi: 10.1177/0883073817739509.
     Google Scholar
  6. Freret ME, Gutmann DH, Insights into optic pathway glioma vision loss from mouse models of neurofibromatosis type I. J Neurosci Res. 2019;97(1):45-46. doi: 10.1002/jnr.24250.
     Google Scholar
  7. Cassina M, Frizziero L, Opocher E, Parrozzani R, Sorrentino U, Viscardi E, Miglionico G, Midena E, Clementi M, Trevisson E. Optic pathway glioma in type 1 neurofibromatosis: Review of its pathogenesis, diagnostic assessment, and treatment recommendations. Cancers. 2019;11:1790. doi: 10.3390/cancers11111790.
     Google Scholar
  8. Shen TT, Sakai O, Curtin HD, Rizzo JF III. Magnetic resonance imaging of primary anterior visual pathway tumors. Int Ophthalmol Clin. 2001;41:171–180.
     Google Scholar
  9. Dutton JJ. Gliomas of the anterior visual pathway. Surv Ophthalmol. 1994;38:427–452.
     Google Scholar
  10. Komotar RJ, Burger PC, Carson BS, Brem H, Olivi A, Goldthwaite PT, et al. Pilocytic and pilomyxoid hypothalamic/chiasmatic astrocytomas. Neurosurgery. 2004;54:72–80.
     Google Scholar
  11. Thomas RP, Gibbs IC, Xu LW, Recht L. Treatment options for optic pathway gliomas. Curr Treat. Options Neurol. 2015;17:2. doi: 10.1007/s11940-014-0333-2.
     Google Scholar
  12. Ahn Y, Cho BK, Kim SK, Chung YN, Lee CS, Kim IH, et al. Optic pathway glioma: outcome and prognostic factors in a surgical series. Childs Nerv Syst. 2006;22:1136–1142.
     Google Scholar
  13. Jahraus CD, Tarbell NJ. Optic pathway gliomas. Pediatr Blood Cancer. 2006;46:586–596.
     Google Scholar
  14. Packer RJ, Savino PJ, Bilaniuk LT, Zimmerman RA, Schatz NJ, Rosenstock JG, et al. Chiasmatic gliomas of childhood. A reappraisal of natural history and effectiveness of cranial irradiation. Childs Brain. 1983;10:393–403.
     Google Scholar
  15. Packer RJ, Bilaniuk LT, Cohen BH, Braffman BH, Obringer AC, Zimmerman RA, et al. Intracranial visual pathway gliomas in children with neurofibromatosis. Neurofibromatosis. 1988;1:212–222.
     Google Scholar
  16. Listernick R, Ferner RE, Liu GT, Gutmann DH. Optic pathway gliomas in neurofibromatosis 1: controversies and recommendations. Ann Neurol. 2007;189–198.
     Google Scholar
  17. Fuss M, Hug EB, Schaefer RA, Nevinny-Stickel M, Miller DW, Slater JM, et al. Proton radiation therapy (PRT) for pediatric optic pathway gliomas: comparison with 3D planned conventional photons and a standard photon technique. Int J Radiat Oncol Biol Phys. 1999;45:1117–1126.
     Google Scholar
  18. Grabenbauer GG, Schuchardt U, Buchfelder M, Rodel CM, Guek G, Marx M, et al. Radiation therapy of opticohypothalamic gliomas (OHG)—radiographic response, vision, and late toxicity. Radiother Oncol. 2000;54:239–245.
     Google Scholar
  19. Yousefi O, Azami P, Sabahi M, Dabecco R, Adada B, Borghei-Razavi H. Management of Optic Pathway Glioma: A Systematic Review and Meta-Analysis. Cancers (Basel). 2022;14(19):4781. doi: 10.3390/cancers14194781.
     Google Scholar
  20. Shukla G, Alexander GS, Bakas S, et al. Advanced magnetic resonance imaging in glioblastoma: a review. Chinese Clin Oncol.2017;6(4):40-51. doi:10.21037/cco.2017.06.28.
     Google Scholar
  21. Macdonald DR, Cascino TL, Schold SC, et al. Response criteria for Phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277–80. doi: 10.1200/JCO.1990.8.7.1277.
     Google Scholar
  22. Hawkins MG, Friedman MA National Cancer Institute’s evaluation of unconventional cancer treatments. J Natl Cancer Inst. 1992;84:1699-1702.
     Google Scholar
  23. Burzynski SR, Janicki TJ, Burzynski GS. Antineoplastons A10 and AS2-1 in the treatment of children with optic pathway glioma: Final report for BT-23. Cancer Clin Oncol. 2017;6:25-35.
     Google Scholar
  24. Burzynski SR. Antineoplastons: Biochemical defense against cancer. Physiol Chem Phys. 1976;8:275-279.
     Google Scholar
  25. Burzynski SR. Synthetic antineoplastons and analogs: Drugs of the future. 1986;11:679-688.
     Google Scholar
  26. Burzynski SR, Patil S. The effect of Antineoplaston A10 and AS2-1 and metabolites of sodium phenylbutyrate on gene expression in glioblastoma multiforme. J Cancer Ther. 2014;5:929-945.
     Google Scholar
  27. Burzynski SR, Janicki T, Burzynski G. Comprehensive genomic profiling of recurrent classic glioblastoma in a patient surviving eleven years following antineoplaston therapy. Cancer Clin Oncol. 2015;4(2):41-52.
     Google Scholar
  28. Burzynski SR, Conde AB, Peters A, Saling B, Ellithorpe R, Daugherty JP, Nacht CH. A Retrospective Study of Antineoplastons A10 and AS2-1 in Primary Brain Tumors. Clin Drug Invest. 1999;18:1-10.
     Google Scholar
  29. Burzynski SR, Weaver RA, Lewy RI, Janicki TJ, Jurida GF, et al. Phase II study of Antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma: A preliminary report. Drugs in R & D. 2004;5:315-326. doi.10.2165/0012.
     Google Scholar
  30. Burzynski SR, Lewy RI, Weaver R, Janicki T, Jurida G, Khan M, Larisma CB, Paszkowiak J, Szymkowski B. Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme. Integ Cancer Ther. 2004;3:257-261. doi: 10.1177/1534735404267748.
     Google Scholar
  31. Burzynski SR, Weaver R, Bestak M, Janicki T, Szymkowski B, Jurida G, Khan M, Dolgopolov, V. Treatment of primitive neuroectodermal tumors (PNET) with antineoplastons A10 and AS2-1 (ANP): Preliminary results of phase II studies. Neuro Oncol. 2004;6:428.
     Google Scholar
  32. Burzynski SR, Weaver RA, Janicki, T, Szymkowski B, Jurida G, Khan M, Dolgopolov V. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineoplastons A10 and AS2-1. Integ Cancer Ther. 2005;4(2):168-177. doi: 10.1177/ 1534735404267748.
     Google Scholar
  33. Burzynski SR, Weaver R, Bestak M, Janicki T, Jurida G., Szymkowski B, Khan M, Dolgopolov V. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in children with atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system: A preliminary report. Neuro Oncol. 2004;6:427.
     Google Scholar
  34. Burzynski SR. Targeted Therapy for Brain Tumors. In: Brain Cancer Therapy and Surgical Interventions. Yang AV, Ed. Nova Science Publishers, Inc, New York. 2006, vol. 27, ch. 4, pp. 77-111.
     Google Scholar
  35. Burzynski SR, Janicki, TJ, Weaver RA, Burzynski B. Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive brainstem glioma. Integ Cancer Ther. 2006;5(1):40-47. doi: 10.1177/1534735405285380.
     Google Scholar
  36. Burzynski SR. Treatments for astrocytic tumors in children: Current and emerging strategies. Ped Drugs. 2006;8:167-168.
     Google Scholar
  37. Doi.org/10.2165/00148581-200608030-00003.
     Google Scholar
  38. Burzynski SR. Recent clinical trials in diffuse intrinsic brainstem glioma. Cancer Ther. 2007;5:379- 390.
     Google Scholar
  39. Burzynski SR, Burzynski GS, Janicki TJ. Recurrent glioblastoma multiforme: A strategy for long-term survival. J Cancer Ther. 2014;5:957-976. doi.org/10.4236/jct.2014.510101.
     Google Scholar
  40. Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A. A phase II study of antineoplastons A10 and AS2-1 in children with high-grade glioma: Final report (Protocol BT-06) and review of recent trials. J Cancer Ther. 2014;5:565-577. doi.org/10.4236/jct.2014.56065.
     Google Scholar
  41. Burzynski SR, Janicki TJ, Burzynski GS. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme: Final report (Protocol BT-21). J Cancer Ther. 2014;5:946-956. doi.org/10.4236/jct.2014.510100.
     Google Scholar
  42. Burzynski SR, Janicki TJ, Burzynski, GS, Marszalek A, Brookman S. A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors: Final report (Protocol BT-22). J Cancer Ther. 2014;5:977-988. doi.org/10.4236/ jct.2014.510102.
     Google Scholar
  43. Burzynski SR, Janicki TJ, Burzynski GS, Brookman S. Preliminary findings on the use of targeted therapy with pazopanib and other agents in combination with sodium phenylbutyrate in the treatment of glioblastoma multiforme. J Cancer Ther. 2014;5:1423-1437.
     Google Scholar
  44. Burzynski GS, Janicki TJ, Marszalek A. Long-term survival (>20 years) of a child with brainstem glioma treated with antineoplastons A10 and AS2-1: A case report. Neuro Oncol. 2014;11:16.
     Google Scholar
  45. Burzynski SR, Janicki TJ, Burzynski GS, Marszalek. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Childs Nerv Syst. 2014;30:2051-2061. doi.org/ 10.1007/s00381- 014-2401-z.
     Google Scholar
  46. Burzynski S, Janicki T, Burzynski G, Marszalek A. Long-term survival (>13 years) in a child with recurrent diffuse pontine gliosarcoma: A case report. J Ped Hematol Oncol. 2015;36:433-439.
     Google Scholar
  47. Doi: 10.1097/MPH.0000000000000020
     Google Scholar
  48. Burzynski SR, Janicki T, Burzynski G. A phase II study of Antineoplastons A10 and AS in adult patients with primary brain tumors: Final report (Protocol BT-09), J Cancer Ther. 2015;6:1063-1074. doi.org/10.4236/jct.2015.612116.
     Google Scholar
  49. Burzynski SR, Burzynski G, Janicki J, Marszalek A. Complete response and Long-term survival (>20 years) of a child with tectal glioma: A case report. Pediatr Neurosurg. 2015;50:99-103. doi: 10.1159/000369907.
     Google Scholar
  50. Burzynski SR, Janicki TJ, Burzynski G. A phase II study of Antineoplastons A10 and AS2-1 injections in adult patients with recurrent anaplastic astrocytoma: Final report (Protocol BT-15). Cancer Clin Oncol. 2015;442:13-23.
     Google Scholar
  51. Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A. A Phase II Study of Antineoplastons A10 and AS2-1 in adult patients with newly diagnosed anaplastic astrocytoma: Final report (Protocol BT-08). Cancer Clin Oncol. 2015;4:28-38.
     Google Scholar
  52. Burzynski SR, Burzynski GS, Marszalek A, Janicki J, Martinez-Canca J. Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma treated with Antineoplastons A10 and AS2-1. J Neurol Stroke. 2015;2(3):00054.
     Google Scholar
  53. Burzynski SR, Burzynski GS, Marszalek A, Janicki TJ, Martinez-Canca JF. Long-term survival over 21 years and pathologically confirmed complete response in pediatric anaplastic astrocytoma: A case report. J Neurol Stroke. 2015;2(6):00072.
     Google Scholar
  54. Burzynski SR, Burzynski GS, Brookman S. A case of sustained objective response of recurrent/progressive diffuse intrinsic pontine glioma with phenylbutyrate and targeted agents. J Cancer Ther. 2015;6:40-44. doi: 10.4236/jct.2015.61006.
     Google Scholar
  55. Burzynski SR, Janicki, T, Burzynski G, Marszalek A. A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas: The report on non-diffuse intrinsic pontine glioma (Protocol BT-11). J Cancer Ther. 2015;6:334-344. doi: 10.4236/jct.2017.82015.
     Google Scholar
  56. Burzynski S, Janicki TJ, Burzynski GS. Primary CNS tumors and leptomeningeal, disseminated, and/or multicentric disease in children treated in phase II studies with antineoplastons A10 and AS2-1. Cancer Clin Oncol. 2016;5(2):38-48. doi.10.5539/cco.v5n2938.
     Google Scholar
  57. Burzynski SR, Janicki TJ, Burzynski GS. A phase II study of antineoplastons A10 and AS2-1 in children with low-grade astrocytomas: Final report (Protocol BT-13). J Cancer Ther. 2016;7(12):837-850.
     Google Scholar
  58. Burzynski SR, Janicki TJ, Burzynski GS, Marszalek A. A phase II study of Antineoplastons A10 and AS2-1 in children with brain tumors: Final report (Protocol BT-10). J Cancer Ther. 2017;8:173-187.
     Google Scholar
  59. Burzynski SR, Janicki T, Beenken, S. Treatment of recurrent glioblastoma multiforme (rGBM) with Antineoplaston AS2-1 in combination with targeted therapy. Cancer Clin Oncol. 2019;8:1-15.
     Google Scholar
  60. Burzynski, SR, Janicki, T, Burzynski, GS, Beenken, S. Long-term survival (27.7 years) following IV Antineoplaston Therapy (ANP) in a 36-year-old-female with a progressive diffuse intrinsic pontine glioma (DIPG). Int J Radiol Imaging Technol. 2021;7:073-078. doi:10.23937/2572-3235.1510073.
     Google Scholar
  61. Burzynski, SR, Burzynski, GS, Janicki, T, Beenken S. Long-term survival (23 years) in a 26-year-old male after Antineoplaston therapy for a progressive, diffuse intrinsic pontine glioma: A case report. Int J Brain Disorder Treat. 2021;6:038-044. doi.org/10.23937/2469-5866/1410038.
     Google Scholar
  62. Burzynski, SR, Janicki T, Burzynski GS, Beenken S. Resolution of clinical signs, a complete response, and long-term survival (>23 Years) in a 3 and ½ month female with a newly diagnosed diffuse intrinsic pontine glioma treated with antineoplastons. Biomed Res Clin Prac. 2021;6:1-6. doi: 10.15761/BRCP.1000220.
     Google Scholar
  63. Burzynski, SR, Janicki T, Burzynski GS, Beenken S. Diffuse intrinsic pontine glioma in an 11-year-old female treated with antineoplastons: Complete response and > 25-year survival. Pediatr Neonatal Med. 2021;1(2):1-5. doi: 10.33425/2768-0363.1010.
     Google Scholar
  64. Burzynski SR, Janicki T, Burzynski GS, Beenken S. A 25-year-old female with diffuse intrinsic pontine glioma surviving for more than nine years following treatment with antineoplastons. Int J Clin Oncol Cancer Res. 2022;1-7. doi: 10.11648/j.ijcocr.20220701.
     Google Scholar
  65. Burzynski SR, Burzynski GS, Janicki T, Beenken S. Twenty-two-year survival in a 15-year-old female with a recurrent posterior fossa ependymoma treated with antineoplastons. Oncol Clin Res. 2022;3(1):99-105.
     Google Scholar
  66. Burzynski S, Burzynski G, Janicki T, Beenken, S. Recurrent and progressive ganglioglioma in an 11-year-old male treated with antineoplastons: Partial response with more than nine years and nine months survival and complete resolution of clinical symptoms/signs. Biomed Res J. 2022;37:1-13.
     Google Scholar
  67. Burzynski S, Burzynski G, Janicki T, Beenken, S. Newly diagnosed Multicentric Pilocytic Astrocytoma: Complete Response and >22 Years Survival in a Six Year and Nine-month-old Female Treated with Antineoplastons. Internat J Clin Oncol and Cancer Res. 2022;7(3):76-82. doi: 10.11648/j.ijcocr.20220703.15.
     Google Scholar
  68. Burzynski S, Burzynski G, Janicki T, Beenken, S. Outcomes in Four Children with Persistent, Recurrent, and Progressive Gangliogliomas Treated in Phase II Studies with Antineoplastons A10 and AS2-1. Neurol Neurosci. 2022;3(3):1-9. doi: 10.33425/2692-7918.1036.
     Google Scholar
  69. Burzynski S, Burzynski G, Janicki T, Beenken, S. Recurrent/Persistent Glioblastoma: Complete Response and 24 Years Disease-Free-Survival in a 45-Year-Old Female Treated with Antineoplastons. Cancer Studies Therap. 2022;7(3):1-6. doi: 10.31038 CTS.2022733.
     Google Scholar
  70. Burzynski S, Burzynski G, Janicki T, Beenken, S. Newly diagnosed Glioblastoma: Partial Response and > 27 Years Overall Survival in a 37-Year-Old Male Treated with Antineoplastons. Recent Adv Clin Trials. 2022;1(2):1-7.
     Google Scholar
  71. Burzynski S, Burzynski G, Janicki T, Beenken S. Newly diagnosed Anaplastic Astrocytoma: > 23 Year Survival in a 31-Year and 11-Month-Old Female Treated with Antineoplastons. Neurol Neurosci. 2023;4(2):1-6.
     Google Scholar